

Jonas Bjerring Olesen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9406367/publications.pdf>

Version: 2024-02-01

71
papers

5,545
citations

218592

26
h-index

106281

65
g-index

71
all docs

71
docs citations

71
times ranked

6532
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. <i>BMJ: British Medical Journal</i> , 2011, 342, d124-d124.	2.4	1,143
2	Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2012, 367, 625-635.	13.9	795
3	The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1172-1179.	1.8	414
4	Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a "real world" nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2011, 106, 739-749.	1.8	393
5	Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention. <i>Circulation</i> , 2012, 126, 1185-1193.	1.6	381
6	Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction. <i>Circulation</i> , 2011, 123, 2226-2235.	1.6	291
7	Net Clinical Benefit of Antithrombotic Therapy in Patients With Atrial Fibrillation and Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2471-2482.	1.2	259
8	Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. <i>Europace</i> , 2015, 17, 187-193.	0.7	152
9	Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. <i>European Heart Journal</i> , 2017, 38, ehv658.	1.0	142
10	Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	109
11	Long-Term Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drug Use According to Time Passed After First-Time Myocardial Infarction. <i>Circulation</i> , 2012, 126, 1955-1963.	1.6	102
12	Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. <i>Europace</i> , 2015, 17, 18-23.	0.7	102
13	Risk Factors for Stroke and Thromboembolism in Relation to Age Among Patients With Atrial Fibrillation. <i>Chest</i> , 2012, 141, 147-153.	0.4	96
14	Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 964-971.	0.9	82
15	Relation of Nonsteroidal Anti-inflammatory Drugs to Serious Bleeding and Thromboembolism Risk in Patients With Atrial Fibrillation Receiving Antithrombotic Therapy. <i>Annals of Internal Medicine</i> , 2014, 161, 690.	2.0	81
16	Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. <i>European Heart Journal</i> , 2016, 38, ehv496.	1.0	74
17	Vascular Disease and Stroke Risk in Atrial Fibrillation: A Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2012, 125, 826.e13-826.e23.	0.6	73
18	Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 17-26.	1.2	47

#	ARTICLE	IF	CITATIONS
19	Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 2707-2713.	1.0	45
20	Atrial fibrillation and risk of stroke: a nationwide cohort study. <i>Europace</i> , 2016, 18, 1689-1697.	0.7	45
21	Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1790-1800.	1.2	41
22	Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2150-2158.	1.2	37
23	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study. <i>Scientific Reports</i> , 2017, 7, 3347.	1.6	36
24	Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin - A Nationwide Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0141377.	1.1	31
25	Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. <i>European Heart Journal</i> , 2019, 40, 3782-3790.	1.0	29
26	Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. <i>Europace</i> , 2015, 17, 1215-1222.	0.7	28
27	Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study. <i>European Heart Journal</i> , 2018, 39, 1698-1705a.	1.0	28
28	Atrial Fibrillation and Vascular Disease - A Bad Combination. <i>Clinical Cardiology</i> , 2012, 35, 15-20.	0.7	27
29	Dialysis-Requiring Acute Kidney Injury in Denmark 2000-2012: Time Trends of Incidence and Prevalence of Risk Factors - A Nationwide Study. <i>PLoS ONE</i> , 2016, 11, e0148809.	1.1	27
30	One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study. <i>European Heart Journal</i> , 2020, 41, 1112-1119.	1.0	27
31	Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation. <i>JAMA Network Open</i> , 2018, 1, e180171.	2.8	25
32	Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation. <i>Europace</i> , 2018, 20, e78-e86.	0.7	22
33	Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2291-2299.	1.8	21
34	Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 91.	0.7	21
35	Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006058.	0.9	21
36	Symptomatic Venous Thromboembolism Following Fractures Distal to the Knee. <i>Journal of Bone and Joint Surgery - Series A</i> , 2015, 97, 470-477.	1.4	20

#	ARTICLE	IF	CITATIONS
37	Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 220-227.	1.4	20
38	Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 292-300.	1.4	20
39	Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2901-2909.	1.2	19
40	Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis. <i>Thrombosis Research</i> , 2015, 136, 732-738.	0.8	18
41	Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1357-1365.	1.2	18
42	Trends in One-Year Outcomes of Dialysis-Requiring Acute Kidney Injury in Denmark 2005-2012: A Population-Based Nationwide Study. <i>PLoS ONE</i> , 2016, 11, e0159944.	1.1	18
43	Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. <i>Heart</i> , 2018, 104, 912-920.	1.2	16
44	All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f93-f100.	1.4	16
45	Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study. <i>Thrombosis Journal</i> , 2019, 17, 21.	0.9	14
46	Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f3-f10.	1.4	13
47	Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings. <i>Europace</i> , 2016, 18, 492-500.	0.7	11
48	Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study. <i>Thrombosis Research</i> , 2019, 178, 101-109.	0.8	11
49	Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant - Danish nationwide cohort study. <i>BMJ Open</i> , 2019, 9, e028468.	0.8	11
50	Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	10
51	Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. <i>BMC Neurology</i> , 2015, 15, 225.	0.8	9
52	The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation. <i>Europace</i> , 2019, 21, 572-580.	0.7	9
53	Benefit of Clopidogrel Therapy in Patients With Myocardial Infarction and Chronic Kidney Disease - A Danish Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	6
54	Effect of government interventions to contain the COVID-19 pandemic on incidence of pulmonary embolism - A Danish nationwide register-based cohort study. <i>Thrombosis Research</i> , 2021, 199, 97-100.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 511-521.	0.4	5
56	Comparative thromboembolic risk in atrial fibrillation patients with and without a concurrent infection. <i>American Heart Journal</i> , 2018, 204, 43-51.	1.2	4
57	Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 455-462.	1.2	4
58	Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 20-30.	1.4	4
59	The atrial fibrillation epidemic: a validated diagnosis, or not?. <i>Europace</i> , 2014, 16, 1701-1702.	0.7	3
60	Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011-2016. <i>Thrombosis Research</i> , 2017, 160, 19-26.	0.8	3
61	Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 353-362.	1.4	3
62	Thromboembolic and bleeding complications following primary total knee arthroplasty. <i>Bone and Joint Journal</i> , 2021, 103-B, 1571-1577.	1.9	3
63	Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation. <i>PLoS ONE</i> , 2016, 11, e0161768.	1.1	2
64	Familial Clustering of Venous Thromboembolism - A Danish Nationwide Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0169055.	1.1	1
65	Real-world effectiveness and safety of pharmacological thromboprophylaxis in patients undergoing primary total hip and knee arthroplasty: A narrative review. <i>Journal of Orthopaedics</i> , 2020, 19, 166-173.	0.6	1
66	SaO028BONE FRACTURES IN PATIENTS ON RENAL REPLACEMENT THERAPY: DOES DIABETES INCREASE THE RISK?. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
67	Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study. <i>Europace</i> , 2020, 22, 716-723.	0.7	0
68	When Oral Anticoagulation Becomes Difficult. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1309-1310.	1.2	0
69	MO503SAFETY AND EFFICACY OF ANTICOAGULATION IN PATIENTS WITH EGFR$\leq 30\text{ mL}/\text{MIN}/1.73\text{ M}^2\text{ AND ATRIAL FIBRILLATION}$. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
70	MO483CHA2DS2-VASC SCORE IN PATIENTS WITH EGFR$\leq 30\text{ mL}/\text{MIN}/1.73\text{ M}^2\text{ AND ATRIAL FIBRILLATION}$*. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
71	Diabetes increases the risk of bone fractures in patients on kidney replacement therapy: A Danish national cohort study. <i>Bone</i> , 2021, 153, 116158.	1.4	0